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Acetylation by arylamine N-acetyltransferases (NATs) is a major route in the metabolism of numerous drugs and carcinogens. Recent studies suggest
that the same enzymes also catalyze N,O-transacetylation and O-acetylation. A genetic polymorphism of clinical relevance divides the human popu-
lation into slow and rapid acetylators of arylamines. Two human NATs, NATl and NAT2, have recently been characterized by protein purification,
cloning, and functional expression of the respective genes; both were localized to chromosome 8. NAT1 codes for a protein with ubiquitous tissue
distribution and a high affinity for p-aminobenzoic acid and p-aminosalicylic acid, so-called monomorphic substrates. NAT2 codes for a protein pre-
dominantly expressed in liver with a high affinity for sulfamethazine and other polymorphically metabolized drugs. NAT2 was analyzed at the level of
protein, RNA and DNA derived from phenotyped slow and rapid acetylators. Two common (Ml, M2) and one rare (M3) mutant allele were identified
and their mutations characterized. A simple polymerase chain reaction-based DNA test can identify >95% of mutant alleles and predict the pheno-
type. - Environ Health Perspect 102(Suppl 6):213-216 (1994)
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Introduction
Acetylation is an important route of bio-
transformation for a large number of
hydrazine and arylamine drugs and car-
cinogens. Several occupational and food
carcinogens may be activated by acetylation
(1-3). For instance, a number of food-
derived heterocyclic amines are activated by
drug-metabolizing enzymes, including
acetyltransferases. The ultimate mutagen/
carcinogen presumably is an electrophilic
arylnitrenium ion which can react with
DNA and form adducts (4). Reactions
involved in the metabolic activation ofhet-
erocyclic amines include N-hydroxylation
by cytochrome P450 and N- and O-acetyl-
ation by cytosolic arylamine N-acetyltrans-
ferases (CoASAc; NAT, EC 2.3.1.5)
(Figure 1).
Interindividual variation in the acetyla-
tion of several arylamine and hydrazine
compounds in humans was shown to be
genetically determined nearly 40 years ago
with the antituberculosis drug isoniazid
(5). Separation of individuals into either
rapid or slow acetylators is determined by
variation at a single autosomal locus and
This paper was presented at the Fifth International
Conference on Carcinogenic and Mutagenic
N-Substituted Aryl Compounds held 18-21 October
1992 in Wurzburg, Germany.
The studies in the author's laboratory are sup-
ported by the Swiss National Science Foundation.
The data from the author's laboratory mentioned in
this review were generated by Martin Blum, Denis
Grant, Markus Beer, Anne Demierre, Francine
Hoffmann, Franck Broly, and Markus Probst.
Address correspondence to U. A. Meyer,
Biocenter of the University, Klingelbergstr. 70, CH-
4056 Basel, Switzerland. Telephone 41 61 267 22
20. Fax 41 61 267 22 08.
constitutes one of the first discovered
genetic polymorphisms of drug and car-
cinogen metabolism (1-3). The propor-
tions of rapid and slow acetylators vary
remarkably in different ethnic and/or geo-
graphic-origin populations. For example,
the percentage of slow acetylators among
Canadian Eskimos is 5%; whereas it rises
to over 80% among Egyptians and 90%
among Moroccans. Most populations in
Europe and North America have 40 to
70% slow acetylators; Asian populations,
only 10 to 20% slow acetylators (2).
The association ofthe acetylation poly-
morphism with an increased risk ofcertain
cancers (e.g., bladder cancer or colorectal
cancer) has received much recent attention
and has been previously reviewed
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Figure 1. Metabolism of arylamines by hydroxylation
and acetylation to electrophilic aryinitrenium ions.
(2,3,6-8). In contrast to these extensive
clinical studies, until recently little was
known about the molecular mechanism
underlying the acetylation polymorphism.
TheMolecularMechanism ofthe
Acetylation Polymorphism
Early studies in other laboratories estab-
lished that the observed variation in acetyl-
ation of isoniazid and other arylamine and
hydrazine drugs was caused by a difference
in the activity of a cytosolic N-acetyltrans-
ferase (NAT) in the liver (1-3,9,10).
However, some arylamines such as p-
aminobenzoate and p-aminosalicylate also
are N-acetylated, yet are unable to distin-
guish rapid and slow acetylators in vivo or
in liver tissue in vitro (11). These substrates
are called monomorphic, in contrast to the
polymorphic substrates isoniazid, pro-
cainamide, and others. Jenne et al. (9),
during the first detailed biochemical studies
ofdrug acetylation in man, proposed that
two different N-acetyltransferase enzymes
were responsible for the metabolism of
monomorphic and polymorphic aryla-
mines. Moreover, it appeared that the
observed genetic variation in acetylation of
polymorphic substrates was related to dif-
ferences in the quantity of one of these
enzymes present in human liver cytosol,
rather than to altered kinetic characteristics
ofa structural variant. However, subsequent
work using the rabbit as an animal model
for the human acetylation polymorphism
shed doubt on this concept, since kinetic,
biochemical, and immunological experi-
ments in rabbits suggested that a single
species ofenzyme mediates the acetylation
of both monomorphic and polymorphic
substrates (12).
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Therefore, we have done experiments,
both in humans and in rabbits, designed to
clarify the molecular mechanism responsi-
ble for the observed genetic polymorphism
and for the different handling ofso-called
monomorphic and polymorphic substrates.
An additional goal was the development of
a simple genotyping test which could pre-
dict the acetylator phenotype in genomic
DNA ofpatients and volunteers in clinical
studies.
Results and Discussion
Studieswith Purified
N-Acetyltransferases
Two closely related but kinetically distinct
NAT activities, NATI and NAT2, were
purified from frozen human liver and the
polyclonal rabbit antiserum, which recog-
nizes these proteins on Western blots, was
developed (13,14). Microsequencing of
tryptic peptides and comparison with
sequence data from the purified rabbit
enzyme (15) established the identity ofthe
purified enzyme. NAT2 was shown to be
separable on anion exchange resins into
two closely related acetylating enzymes,
NAT2A and NAT2B, which apparently are
translational products derived from the
same gene (11,14). Using a polyclonal
antibody, we saw a close correlation
between the in vitro NAT activity mea-
sured with sulfamethazine and the amount
of immunoreactive protein ofboth NAT2
fractions in cytosols from 50 human livers
(14). Thus, the immunoreactive protein
was markedly decreased or absent in livers
with low N-acetyltransferase activity.
Apparently, as later studies (11) indicated,
NATI is unstable and was not detected.
Furthermore, we observed an excellent cor-
relation between in vitro NAT2 activity,
with immunoreactive protein and acetylator
phenotype determined in vivo using caf-
feine as a probe drug (14). These experi-
ments unequivocally established that the
acetylation polymorphism is due to the
decreased amount of a N-acetyltransferase
enzyme in the liver.
CloningofHuman andRabbit
NATGenes
We first cloned a rabbit NAT cDNA
(16,17) and used it to isolate DNA clones
from a XEMBL3 library constructed with
genomic DNA from an individual charac-
terized in a family study as obligate het-
erozygous rapid acetylator (18). The 18
recombinant clones obtained defined three
different human NAT genes, designated
NATI, NAT2, and NATP. Both NATI
and NAT2 have single coding exons of870
base pairs and high homology (81% for
amino acids, 87% for nucleotides) between
them. These two genes were localized to
human chromosome 8; NATP represents a
pseudogene (18). To determine which
NAT gene codes for the polymorphic
enzyme, NAT1 or NAT2 (i.e., the EcoRI
fragments of 1.3 and 1.9 kilobase pairs
containing these genes) were inserted into
the expression vector p91023 and tran-
siently expressed in COS-1 cells, with
analysis ofthe protein product by Western
blotting and sulfamethazine acetylation
activity (18). We could demonstrate that
NAT2 encodes a protein with identical
mobility on SDS-PAGE and identical
affinity for arylamine substrates as that
exhibited by the NAT2 proteins purified
from human liver (11,13). The NATI
gene product had an apparently lower
mobility and much lower affinity for the
polymorphic substrate sulfamethazine.
The discovery of two separate genes
encoding NATI and NAT2 also resolved
the puzzle ofmonomorphic and polymor-
phic substrates. NAT2 has a high affinity
for polymorphic substrates such as sul-
famethazine and procainamide, whereas
NATI has higher affinities for the
monomorphic substrates p-aminobenzoate
and p-aminosalicylate and is not affected
by the polymorphism. NATI apparently
was missed in our earlier purifications from
frozen human liver because it is unstable
and rapidly degrades upon thawing. The
present data thus support the concept that
the two activities separated on anion
exchange resins NAT2A and NAT2B
(13,14) represent two forms ofpolymor-
phic NAT2 and are derived from a single
gene (11).
Mutations oftheNAT2 GeneCausing
SlowAcetylation
Mutant alleles were initially defined by
restriction fragment analysis ofeither geno-
mic DNA samples from 25 healthy individ-
uals whose acetylator phenotype had been
established by measuring the acetylated
metabolite ofcaffeine in urine, or ofDNA
from 33 human liver samples with known
NAT2 enzyme activity measured with the
substrate sulfamethazine (19). Restriction
fragment length polymorphisms (RFLPs)
generated by KpnI, TaqI, and BamHI seg-
regate with acetylator phenotype and
define three mutant alleles ofNAT2, MI,
M2, and M3. Two of these RFLPs were
also described by Deguchi et al. (20) in a
Japanese population. To explore the molec-
ular mechanism of slow acetylation, we
cloned M1 and M2 genes from genomic
XEMBL3 and kgtlO libraries, respectively,
and compared their sequence to the wild-
type gene (19)(Table 1). Both MI and M2
point mutations causing amino acid
changes in the deduced protein sequence
were combined with silent base substitu-
tions. The silent mutation in MI (481
C->T) alters the recognition sequence for
the restriction enzyme KpnI, explaining the
observed RFLP. In M2, the point mutation
(590 G->A) causes the change in
(Arg197-Glu197) and eliminates a TaqI
restriction site. Studies in additional sam-
ples revealed that MI very frequently has
an additional 3d point mutation at posi-
tion 803 (A803-G) (21,22). A third
mutant allele, M3, apparently rare in the
Caucasian population first examined by us,
has been characterized as cDNA and
sequenced by Ohsako et al. in a Japanese
population (23). M3 has one point muta-
tion (857 G->A) causing an amino acid
change (Gly286->Glu286), a loss of a
BamHI restriction site, and a silent muta-
tion (C282-÷T). We also have observed this
mutant to occur relatively frequently in the
Chinese population (Table 2). Determina-
tion ofthe mutations at position 481, 590,
and 857 is sufficient to define alleles MI,
M2, and M3. The nucleotide substitutions
at position 341 and 803 are virtuallyalways
associated with the 481 T mutation (22).
To dissect the contribution of single
mutations to decreased enzyme protein
chimeric gene constructs betweenwild-type
alleles, M1 and M2 were generated and
transiently expressed in COS-1 cells (19).
Constructs bearing only one of the two
mutations ofallele Ml on expression both
behaved like the normal enzyme, demon-
strating that two nucleotide substitutions
of MI (341 T->C and 481 C-*T) are
required to decrease enzyme protein and
activity. Analysis of the M2-derived con-
structs showed that the silent mutation
(282 C-*T) does not affect the enzyme.
The mutation (590 G->A) causing the
amino acid change (Arg197->Gln197) alone
causes a reduction ofenzyme protein and
activity. When stabilities ofexpressed pro-
teins were compared, the half-lives at 37°C
ofwild-type and MI-derived activities were
identical to wild-type; whereas, that ofM2
appeared markedly reduced (although there
was considerable variation between experi-
ments in the half-lives). Thus, the
(Arg,97-Gln197) mutation ofM2 presum-
ably produces a less stable protein, and the
combination ofthe two nucleotide substi-
tutions in Ml causes defective translation,
possibly due to alterations in transcript sec-
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Table 1. Alleles of NAT2 and their mutations.
Nucleotides at site of mutation [numbering of nucleotides. ]
Designation of allele 282 341 481 590 803 857
Wild-type(rapid, R) C T C G A G
Ml (slow, S, r3) C Cb Tc,d G Gbc G
M2 (slow, S, r2) Td T C A' A G
M3 (slow, S, rl) Td T C G A A'
"According to Blum et al. (18) bMutation causes a change in an amino acid. CMutation generates or eliminates a
restriction site. dSilent mutation, nochange in amino acid.
Table 2. Frequencies ofwild-type and three mutant alleles of NAT2 in different populations.
Allele designation European/Caucasian,a % Japanese,b % Chinese,C %
Wild-type 29.8 68.6 60.2
Ml 40.1 0 7.4
M2 27.9 24.4 26.2
M3 2.2 7.0 6.3
Slow acetylator phenotype, % 40-70 10-20 10-20
aAnalysis by polymerase chain reaction-amplification of 322 alleles of Caucasians from Graf et al. (24) and addi-
tional unpublished studies in the author's laboratory. bData from Deguchi et al. (20). Analysis by restriction frag-
ment length polymorphism of 172 alleles. cData from Hayes et al. (25).
ondary structure. No studies on the mecha-
nism by which M3 causes decreased pro-
tein have been reported.
Development ofaGenotypingAssay
This knowledge on the mutations of M1,
M2, and M3 was used to develop a set of
mutation-specific primers for allele-specific
amplification ofsmall amounts ofDNA by
the polymerase chain reaction (19). Our
present data are summarized in Table 2.
Allele MI had the highest frequency (40%)
and together with M2 (27.9%) accounted
for 68% ofall alleles in the Caucasian pop-
ulation. Of the slow alleles, 54.8% were
Ml, 38.6% M2, 2.2% M3. The phenotype
of 78 of the 81 individuals was correctly
predicted (96.3%, 24). Some apparent
wild-type alleles in slow acetylators proba-
bly carry unknown mutations and account
for approximately 5% ofslow alleles. Thus,
M3 indeed is quite rare in Caucasians. On
the other hand, in a Japanese population
analyzed by RFLP by Deguchi et al. (18),
Ml was not observed, but M3 was repre-
sented at a somewhat higher level of 7%.
Ofall slow alleles, M3 accounted for 22%
in the study of Deguchi et al. (18). These
data suggest that most of the observed
interethnic difference in the occurrence of
the slow acetylator phenotype between
Oriental and Caucasian populations is due
to the almost unique presence at high fre-
quency of MI in Caucasians, where M3
shows a relatively higher incidence in
Oriental populations. Moreover, because of
the high incidence of the slow acetylator
allele in the Caucasian population, only
10% offast acetylators are homozygous for
the wild-type gene and cannot easily be dif-
ferentiated by the usual phenotyping proce-
dure from the predicted approximately
40% heterozygous carriers ofa slow NAT2
allele. These interethnic comparisons were
confirmed in a recent study in a Chinese
population and are summarized in Table 2.
Conclusion
These studies at the protein, RNA, and
DNA level provide a molecular basis for
the clinical and experimental data on slow
acetylation in man. The described DNA
amplification assay for NAT2 mutations
allows the prediction ofthe acetylator phe-
notype in over 95% of individuals tested
with a small sample of DNA, which may
be derived from leucocytes, single hair
roots, buccal epithelia, or any other tissue.
This will allow the genotyping of patients
and volunteers in clinical studies or of
workers at high risk for toxicity upon expo-
sure to arylamine chemicals. The heterolo-
gous expression of NAT genes (4, 11,
17-19) will allow the efficient testing ofnew
substrates for these enzymes and ofthe acti-
vation ofcarcinogens to mutagenic products.
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